Search Medical Condition
Please enter condition
Please choose location
 

North Charleston, South Carolina Clinical Trials

A listing of North Charleston, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (749) clinical trials

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder

While the availability of atypical antipsychotics have increased the therapeutic options available, there remains a need for safer and more effective therapies in the treatment of manic and depressive episodes of bipolar I disorder. Brexpiprazole's specific receptor activity profile likely correlates with its established efficacy in schizophrenia and major depressive ...

Phase

0.0 miles

Learn More »

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

A multicenter, randomized, double-blind trial of Brexpiprazole versus Placebo for the acute treatment of manic episodes, with or without mixed features, associated with bipolar I disorder. This study will also demonstrate the safety and tolerability of brexpiprazole in the study population of males and females aged 18 to 65 years ...

Phase

0.0 miles

Learn More »

Program for Pain & Prescription Opioid Use in Pregnancy

Subjects: Participants will be 200 adult, pregnant women receiving prenatal care and using POs for chronic pain. Women must be willing to consider a PO dose reduction, and cannot meet criteria for a Substance Use Disorder. Specific inclusion and exclusion criteria can be found in the Protections of Human Subjects ...

Phase N/A

0.0 miles

Learn More »

Nurse-Family Partnership Impact Evaluation in South Carolina

This study is an individual-level randomized controlled trial, with randomization post-consent. The study will enroll pregnant women who are income-eligible for Medicaid, less than 28 weeks pregnant, and have not had a previous live birth. All eligible applicants who provide written consent will be randomly assigned either to a treatment ...

Phase N/A

0.0 miles

Learn More »

Study to Evaluate the Efficacy and Safety of REGN2222 for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

This study occurs in two parts: Part A and Part B. The status of Part A is 'Complete'. The status of Part B is 'Recruiting.' Part A of the study is an open-label, PK evaluation of intramuscular (IM) administered REGN2222 in preterm infants for whom palivizumab is not recommended to ...

Phase

0.96 miles

Learn More »

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

This multicenter study will assess the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.

Phase

1.34 miles

Learn More »

A phase III study to evaluate weight gain of ALKS3831 compared to olanzapine in adults with schizophrenia

Phase

3.81 miles

Learn More »

Efficacy and Safety of Dupilumab in Patients 12 to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

To demonstrate the efficacy of dupilumab as a monotherapy in patients ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis (AD)

Phase

3.81 miles

Learn More »

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly ...

Phase

3.81 miles

Learn More »

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

Approximately 290 eligible participants with [chronic kidney disease (CKD) on stable doses of medication] will be randomly assigned to receive a patiromer or placebo starting dose of two packets a day, once a day. All eligible participants will undergo a screening/run-in period (up to 4 weeks) to determine eligibility for ...

Phase

3.81 miles

Learn More »